Of note, the results of our study do not fully reflect the introduction of novel therapies approved for front‐line MM in the 2018 to 2019 time period, specifically the anti‐CD38 monoclonal antibody daratumumab, with the ALCYONE and MAIA trial results first reported in 2018 and 2019, respectively.19, 20. The gene discussed is CD38; the disease is Miyoshi myopathy.